Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.
Products, services, technology
MTx's lead program, potravitug, is planned to start Phase III clinical development in 2026, targeting BK polyomavirus (BKPyV) infection in kidney transplant recipients and has the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients.
Cooperation possibilities
MTx is discovering novel oncology targets using its proprietary DROPZYLLA® platform, a powerful antibody repertoire-copying engine. The company advances programs both internally and through partnerships, offering collaboration opportunities to identify and develop new antibody target pairs.
- http://www.memo-therapeutics.com
- +41 44 515 91 40
- Send an email
Some insights
BKPyV infection in kidney transplant recipients can double kidney-loss risk and triple the risk of death. With no specific antivirals available, MTx’s potravitug could become a first-in-class antibody therapy to control BKPyV and protect graft function.
Our core values are integral to what we do and we believe that adhering to them will be critical to our success. Driven by scientific innovation, we deliver high-quality results, fostered through a collaborative mindset, to make a difference for patients with viral infections and cancer.
Memo Therapeutics AG is proud to be a part of Switzerland's thriving biotech industry. The Swiss biotech ecosystem plays a key role in driving global healthcare innovation and we are open to partnering our proprietary DROPZYLLA® discovery platform.
